News
The recent detention of over a dozen international students on college campuses across the country has raised concerns among ...
Rosella Marie Ruesch, 92, of Florissant, MO, passed away peacefully on Saturday, March 1, 2025.
Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
The Washington Supreme Court has agreed to consider the Washington Farm Bureau’s claim that the Department of Ecology shirked ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Born in Wellington in 1944, Peter struggled at school with what would now be recognised as dyslexia. He left Wellington Tech at age 15 and worked as a tele ...
The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.
7d
Zacks Investment Research on MSNBiotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & MoreIt was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results